Mosunetuzumab (Lunsumio): Mechanism, Pharmacology, Uses & Side Effects
Explore a detailed guide on Mosunetuzumab, including mechanism, pharmacology, clinical use, safety, and FDA approval for follicular lymphoma. Read more
Category: Cancer
Teclistamab in Multiple Myeloma: Mechanism, Structure and Clinical Trial Results
Teclistamab is a BCMA × CD3 bispecific antibody that redirects T cells to kill multiple myeloma cells in relapsed patients. Read more
BCMA-Targeted Therapies in Multiple Myeloma: Teclistamab vs CAR-T vs Antibody-Drug Conjugates
Compare BCMA therapies in multiple myeloma including Teclistamab, CAR-T therapy, and antibody-drug conjugates with mechanisms and clinical outcomes. Read more
BCMA Signaling Pathway in Multiple Myeloma: Structure, Function and Therapeutic Targeting
BCMA signaling drives plasma cell survival in multiple myeloma through BAFF/APRIL activation of NF-κB, PI3K-AKT, and MAPK pathways. Read more
Bispecific Antibodies in Cancer Immunotherapy
Explore the structural design, mechanism of action, and clinical applications of bispecific antibodies in cancer immunotherapy for targeted tumor killing. Read more
p53 Structure, Regulation, and Role in Cancer
Comprehensive review of p53 structure, regulation, activation pathways, and its role in cancer, including mechanisms of mutation and therapeutic targeting. Read more
Hallmarks of Cancer: How Tumors Grow, Spread, and Resist Treatment
Comprehensive guide on cancer hallmarks, tumor microenvironment, systemic effects, and therapeutic strategies for students. Read more
Blinatumomab in B-ALL: BiTE Structure, Mechanism, Resistance & Trials
Blinatumomab is a first-in-class BiTE immunotherapy for B-ALL. Explore its molecular structure, T-cell redirection mechanism, resistance pathways, and clinical trials. Read more
Acute Lymphoblastic Leukemia (ALL) Treatment: A Scientific Overview
Effective treatments for Acute Lymphoblastic Leukemia (ALL), including chemotherapy, CAR T-cell therapy, and stem cell transplant. Read more
Structural Components of a CAR-T Vector Plasmid: A Comprehensive Overview
A CAR-T vector plasmid encodes the engineered receptor that enables T cells to target cancer. It includes key elements for antigen recognition, cell signaling, and controlled gene expression. Read more